crovalimab   Click here for help

GtoPdb Ligand ID: 12790

Synonyms: crovalimab-akkz | Piasky® | RG-6107 | RG6107 | Senkai® (China) | SKY59
Approved drug Immunopharmacology Ligand
crovalimab is an approved drug (China NMPA, FDA & EMA (2024))
Compound class: Antibody
Comment: Crovalimab (SKY59/RG6107) is a long-acting anti-C5 recycling monoclonal antibody [2,6]. The antibody is engineered to bind C5 in a pH-dependent manner. It binds strongly to C5 in the plasma, but in the acidic conditions within the endosome the antibody-C5 immune complex dissociates. The free antibody is re-cycled and can bind more plasma C5, to provide sustained complement inhibition. The C5 released in the endosome is trafficked to the lysosome for degradation. Crovalimab is proposed as a treatment for complement-mediated disorders such as paroxysmal nocturnal hemoglobinuria (PNH) [5] and Lupus nephritis.
Selectivity at ligand targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
complement C5 Hs Antibody Binding 9.8 pKd - 6
⤷ pKd 9.8 (Kd 1.5x10-10 M) [6]
Description: Binding affinity at pH7.4